Risk factors for perihilar cholangiocarcinoma: A hospital-based case-control study

Liver International

Volumn 35, Issue 3, 2015, Pages 1048-1053

  Lee, Ban Seok ^a,b   Cha, Byung Hyo ^b   Park, Eun Cheol ^a   Roh, Jaehoon ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Cheju Halla General Hospital   (South Korea)

Author keywords

Choledocholithiasis; Diabetes mellitus; Hepatolithiasis; Perihilar cholangiocarcinoma; Risk factor

Indexed keywords

AGED; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT STONE; CANCER PATIENT; COMMON BILE DUCT STONE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PERIHILLAR CHOLANGIOCARCINOMA; RISK FACTOR; SMOKING; BILE DUCT NEOPLASMS; CASE CONTROL STUDY; KLATSKIN TUMOR; MIDDLE AGED; MULTIVARIATE ANALYSIS; SOUTH KOREA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HUMANS; KLATSKIN TUMOR; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REPUBLIC OF KOREA; RISK FACTORS;

EID: 84922690109     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12618     Document Type: Article

References (28)

1. Khan SA, Davidson BR, Goldin RD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 2012; 61: 1657-69.
2. Welzel TM, McGlynn KA, Hsing AW, O'Brien TR, Pfeiffer RM. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 2006; 98: 873-5.
3. Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol 2009; 15: 4240-62.
4. Ito F, Cho CS, Rikkers LF, Weber SM. Hilar cholangiocarcinoma: current management. Ann Surg 2009; 250: 210-8.
5. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology 2011; 54: 173-84.
6. Jing W, Jin G, Zhou X, et al. Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis. Eur J Cancer Prev 2012; 21: 24-31.
7. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 2013; 145: 1215-29.
8. Todani T, Watanabe Y, Narusue M, Tabuchi K, Okajima K. Congenital bile duct cysts: classification, operative procedures, and review of thirty-seven cases including cancer arising from choledochal cyst. Am J Surg 1977; 134: 263-9.
9. Choi BI, Han JK, Hong ST, Lee KH. Clonorchiasis and cholangiocarcinoma: etiologic relationship and imaging diagnosis. Clin Microbiol Rev 2004; 17: 540-52.
10. Kanazawa M, Yoshiike N, Osaka T, et al. Criteria and classification of obesity in Japan and Asia-Oceania. World Rev Nutr Diet 2005; 94: 1-12.
11. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-53.
12. Patel T. Cholangiocarcinoma-controversies and challenges. Nat Rev Gastroenterol Hepatol 2011; 8: 189-200.
13. Lim JH, Park CK. Pathology of cholangiocarcinoma. Abdom Imaging 2004; 29: 540-7.
14. Bonney GK, Craven RA, Prasad R, et al. Circulating markers of biliary malignancy: opportunities in proteomics? Lancet Oncol 2008; 9: 149-58.
15. Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 2014; 60: 1268-89.
16. Cai W-K, Sima H, Chen B-D, Yang G-S. Risk factors for hilar cholangiocarcinoma: a case-control study in China. World J Gastroenterol 2011; 17: 249-53.
17. Zhou Y, Zhou Q, Lin Q, et al. Evaluation of risk factors for extrahepatic cholangiocarcinoma: ABO blood group, hepatitis B virus and their synergism. Int J Cancer 2013; 133: 1867-75.
18. Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 2012; 57: 69-76.
19. Alvaro D, Barbaro B, Franchitto A, et al. Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol 2006; 169: 877-88.
20. Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 2001; 60: 91-106.
21. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007; 28: 20-47.
22. Welzel TM, Graubard BI, Zeuzem S, et al. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 2011; 54: 463-71.
23. Welzel TM, Graubard BI, El-Serag HB, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 2007; 5: 1221-8.
24. Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005; 128: 620-6.
25. Hsing AW, Zhang M, Rashid A, et al. Hepatitis B and C virus infection and the risk of biliary tract cancer: a population-based study in China. Int J Cancer 2008; 122: 1849-53.
26. Choi D, Lim JH, Lee KT, et al. Cholangiocarcinoma and Clonorchis sinensis infection: a case-control study in Korea. J Hepatol 2006; 44: 1066-73.
27. Kim TS, Cho SH, Huh S, et al. A nationwide survey on the prevalence of intestinal parasitic infections in the Republic of Korea, 2004. Korean J Parasitol 2009; 47: 37-47.
28. Bae JM. Regional differences in the occurrence of cancers on biliary system in Korea: a descriptive epidemiological study. Korean Public Health Res 2012; 38: 49-55.